BioSpace News Archive

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced confirmation of SARS-CoV-2 antiviral activity of ADX-1612, in addition to novel anti-inflammatory activity in SARS-CoV-2-infected primary human cells in preclinical studies.

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today congratulated ImmunityBio, Inc. (“ImmunityBio”) and NantKwest, Inc. (NASDAQ: NK) (“NantKwest”) on their proposed merger and announced plans to create a leading immunotherapy and cell therapy company.

Omniome, Inc., developer of an innovative DNA sequencing platform capable of delivering unsurpassed sequencing accuracy, announces the promotion of Kelly Perez to Chief Operating Officer.

CANbridge Pharmaceuticals Inc., a company developing and commercializing innovative drugs to treat rare diseases and targeted cancers, announced that it has appointed Justin Lu to the position of General Manager of China, responsible for setting up and operating commercial operations in China

CDI-45205 holds potential as a therapeutic and as a prophylactic to protect against coronavirus transmission, including SARS-CoV-2

In an effort to help identify both new and prior users of opioids who may be at risk for opioid use harm and to ultimately help prevent misuse, Prime Therapeutics LLC (Prime) is expanding its predictive models beyond Medicare, to now

Valo Health, LLC (Valo) , has announced an exclusive drug discovery and development partnership with Global Genomics Group, (G3), giving Valo access to the largest and most-detailed cardio-metabolic da

New Peer-reviewed Article Publishes Results of Clinical Study Testing Safety and Efficacy of Remote Electrical Neuromodulation for Acute Treatment of Migraine in Patients Aged 12-17

The Barer Institute, a cancer drug development initiative of Rafael Holdings, Inc. , (NYSE: RFL), today announced that it has reached an agreement with Princeton University’s Office of Technology Licensing for technology from the laboratory of Professor Joshua Rabinowitz , in the Department of Chemistry, Princeton University ,

Nektar Therapeutics (NASDAQ: NKTR) today announced that it agreed to sell to entities managed by Healthcare Royalty Management, LLC (HCR) its royalties on future sales of ADYNOVATE, under Nektar’s agreement with Baxalta Incorporated, a Takeda company, and MOVANTIK, under Nektar’s agreement with AstraZeneca AB. Under the terms of th